Alternative Medicine Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Alternative Medicine Times.

Press releases published on October 19, 2026

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
Syncromune to Present Updated Long-Term Overall Survival Data from Phase 1 Trial of SYNC-T Therapy SV-102 in Metastatic Prostate Cancer at ESMO Congress 2026
Rivus Pharmaceuticals to Present Preclinical Obesity Data for Muscle-Preserving, Oral GLP-1 RV-8451 at ObesityWeek®
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
Stingray Unveils Ford Streaming Radio and Lincoln Streaming Radio Apps to Enhance the In-Vehicle Audio Experience
Medera's Novoheart Technology Powers Advanced Human Cardiac Disease Modeling at Singapore's New CIPHER Research Centre
Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026
Hyperion DeFi Schedules Third Quarter Earnings Call for Thursday, November 12 at 8:00 a.m. ET
Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S.
COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
Ritedose Partners with Newberry College to Launch Leadership Development Program
Allied Announces Appointment of Donald Clow to the Board of Trustees and Board Committee Chair Changes
Third Partners Launches 3P/AI as Lean Sustainability Teams Face California’s Nov. 10 Deadline
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases
SL Green Refinances 245 Park Avenue for $2.0 Billion
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2026
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Glass House Brands Reports Preliminary Unaudited Third Quarter Financial Results and Resignation of John Nichols Jr. from Board of Directors

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Alternative Medicine Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.